Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CFO Sells 10,000 Shares of Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $7.88, for a total transaction of $78,800.00. Following the transaction, the chief financial officer now directly owns 26,299 shares of the company’s stock, valued at $207,236.12. This represents a 27.55 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Zynex Stock Up 3.6 %

Shares of NASDAQ ZYXI opened at $8.09 on Monday. Zynex, Inc. has a 52-week low of $7.15 and a 52-week high of $13.77. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The business has a fifty day moving average of $8.30 and a two-hundred day moving average of $8.36. The stock has a market cap of $257.63 million, a PE ratio of 53.93 and a beta of 0.49.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The firm had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The company’s revenue for the quarter was up .1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.10 earnings per share. As a group, equities research analysts expect that Zynex, Inc. will post 0.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Royal Bank of Canada reduced their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Zynex in a report on Friday, December 6th.

Hedge Funds Weigh In On Zynex

A number of institutional investors and hedge funds have recently bought and sold shares of ZYXI. JPMorgan Chase & Co. increased its stake in shares of Zynex by 3.3% in the third quarter. JPMorgan Chase & Co. now owns 40,985 shares of the company’s stock valued at $334,000 after buying an additional 1,318 shares in the last quarter. Gladius Capital Management LP grew its position in shares of Zynex by 53.4% during the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock worth $41,000 after buying an additional 1,742 shares during the period. Principal Financial Group Inc. grew its holdings in Zynex by 10.4% during the 2nd quarter. Principal Financial Group Inc. now owns 19,525 shares of the company’s stock worth $182,000 after acquiring an additional 1,846 shares during the period. Jane Street Group LLC boosted its position in shares of Zynex by 8.9% in the 3rd quarter. Jane Street Group LLC now owns 23,530 shares of the company’s stock worth $192,000 after purchasing an additional 1,929 shares during the last quarter. Finally, Cim LLC grew its stake in shares of Zynex by 6.1% during the second quarter. Cim LLC now owns 43,581 shares of the company’s stock worth $406,000 after purchasing an additional 2,508 shares during the period. Institutional investors and hedge funds own 29.68% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.